前沿速览009期| CAR-T治B淋 前沿览新知
01
靶向B细胞和长寿命浆细胞的免疫疗法可有效消除预先存在的供体特异性异体抗体
Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies
第一作者：Zhang Z
Cell Rep Med (IF=14.3). 2023 Dec 19;4(12):101336.
全文网址：https://www.sciencedirect.com/science/article/pii/S2666379123005530
02
多中心开发基于PET的风险评估工具，可用于预测接受CAR-T细胞治疗的大B细胞淋巴瘤患者的产品特定性治疗结局
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
第一作者：Voltin CA
Eur J Nucl Med Mol Imaging (IF=9.1). 2023 Dec 20.
全文网址：https://link.springer.com/content/pdf/10.1007/s00259-023-06554-0.pdf
03
Axicabtagene Ciloleucel输注之前使用苯达莫司汀进行清淋是安全的，并且与炎症性细胞因子的减少有关
Bendamustine Lymphodepletion Before Axicabtagene Ciloleucel Is Safe and Associates with Reduced Inflammatory Cytokines
第一作者：Ghilardi G
Blood Adv (IF=7.5). 2023 Dec 19:bloodadvances.2023011492.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011492/506669/Bendamustine-Lymphodepletion-Before-Axicabtagene
04
二线使用Lisocabtagene maraleucel治疗复发或难治性弥漫大B细胞淋巴瘤的成本效益分析
Cost-Effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma
第一作者：Choe JH
Blood Adv (IF=7.5). 2023 Dec 28:bloodadvances.2023011793.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011793/506783/Cost-Effectiveness-of-second-line-lisocabtagene
05
病例报告：自体干细胞移植后行CD19 CAR-T细胞疗法可成功治疗伴TP53突变的R/R CD20阴性转化滤泡淋巴瘤
Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with TP53 mutation
第一作者：Zhang J
Front Immunol (IF=7.3). 2023 Dec 8;14:1307242.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10739420/
06
CAR-T细胞治疗中门诊给药 vs. 住院给药对血液肿瘤患者的临床、经济和人文结局的影响：系统文献综述
The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review
第一作者：Hansen DK
Cancers (Basel) (IF=5.2). 2023 Dec 7;15(24):5746.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10741664/
07
CD30.CAR-T细胞治疗后初发克隆性造血加速
Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy
第一作者：Kapadia CD
Cytotherapy (IF=4.5). 2023 Dec 26:S1465-3249(23)01123-4.
全文网址：https://www.sciencedirect.com/science/article/pii/S1465324923011234
08
在接受CD19 CAR-T细胞治疗的继发性中枢神经系统淋巴瘤患者中，放疗可作为桥接和挽救治疗的策略
Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy
第一作者：Ababneh HS
Hematol Oncol (IF=3.3). 2023 Dec 16.
全文网址：https://onlinelibrary.wiley.com/doi/full/10.1002/hon.3243
09
伴继发性中枢神经系统受累的复发/难治性弥漫大B细胞淋巴瘤患者的结局及其是否适合CAR-T细胞治疗的评估
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
第一作者：Harrysson S
Leuk Lymphoma (IF=2.6). 2023 Dec 22:1-4.
全文网址：https://www.tandfonline.com/doi/full/10.1080/10428194.2023.2296361
10
低频PPM1D基因突变可影响CD19 CAR-T细胞治疗大B细胞淋巴瘤的应答
Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma
第一作者：Seipel K
Curr Oncol (IF=2.6). 2023 Dec 13;30(12):10463-10476.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10742331/
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.1-2 valid until 2026.1
供稿与审核：临床开发与医学部